Published in Oncologist on April 09, 2014
Adjuvant Zoledronic Acid in High Risk Giant Cell Tumour of Bone (GCT) (HR-GCT) | NCT00889590
Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone. Ann Surg Oncol (2015) 1.14
Giant cell tumor of bone. Oncologist (2014) 0.91
Giant Cell Tumor of Bone - An Overview. Arch Bone Jt Surg (2016) 0.91
Giant cell tumour of bone: new treatments in development. Clin Transl Oncol (2015) 0.87
Risks and benefits of combining denosumab and surgery in giant cell tumor of bone-a case series. World J Surg Oncol (2016) 0.82
Prognostic impact of reduced connexin43 expression and gap junction coupling of neoplastic stromal cells in giant cell tumor of bone. PLoS One (2015) 0.77
MiR-125b inhibits stromal cell proliferation in giant cell tumor of bone by targeting parathyroid hormone 1 receptor. Iran J Basic Med Sci (2015) 0.77
Cryosurgery/cryoablation in musculoskeletal neoplasms: history and state of the art. Curr Rev Musculoskelet Med (2015) 0.77
Surgery methods and soft tissue extension are the potential risk factors of local recurrence in giant cell tumor of bone. World J Surg Oncol (2016) 0.76
Successful Intravascular Correction of Intratumoral Pseudoaneurysm by Erosion of the Aorta in a Patient with Thoracic Giant Cell Tumor of Bone Responding to Denosumab. Case Rep Oncol Med (2015) 0.75
Freezing Nitrogen Ethanol Composite May be a Viable Approach for Cryotherapy of Human Giant Cell Tumor of Bone. Clin Orthop Relat Res (2017) 0.75
Obstructive hydrocephalus as a result of giant cell tumor of the thoracic spine: A case report. Oncol Lett (2015) 0.75
Advances in sarcoma diagnostics and treatment. Oncotarget (2016) 0.75
Aneurysmal bone cyst secondary to a giant cell tumor of the patella: A case report. Oncol Lett (2016) 0.75
Recurrence Rates and Risk Factors for Primary Giant Cell Tumors around the Knee: A Multicentre Retrospective Study in China. Sci Rep (2016) 0.75
A case of thoracic giant cell tumor of bone and discussion of radiological features and current management practices. Radiol Case Rep (2016) 0.75
Denosumab treatment of inoperable or locally advanced giant cell tumor of bone. Oncol Lett (2016) 0.75
In reply. Oncologist (2014) 0.75
Denosumab: an Emerging Therapy in Pediatric Bone Disorders. Curr Osteoporos Rep (2017) 0.75
How safe and effective is denosumab for bone giant cell tumour? Int Orthop (2017) 0.75
Giant cell tumor of the thoracic spine completely removed by total spondylectomy after neoadjuvant denosumab therapy. Eur Spine J (2017) 0.75
Giant cell tumor of bone revisited. SICOT J (2017) 0.75
A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res (1981) 8.45
Giant-cell tumor of bone. J Bone Joint Surg Am (1987) 7.92
Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol (2010) 6.47
From the archives of AFIP. Imaging of giant cell tumor and giant cell reparative granuloma of bone: radiologic-pathologic correlation. Radiographics (2001) 3.60
Treatment of giant-cell tumors of long bones with curettage and bone-grafting. J Bone Joint Surg Am (1999) 3.45
Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol (2013) 3.23
Failure mode classification for tumor endoprostheses: retrospective review of five institutions and a literature review. J Bone Joint Surg Am (2011) 3.23
Recurrence of giant-cell tumors of the long bones after curettage and packing with cement. J Bone Joint Surg Am (1994) 2.86
Giant-cell tumor of bone. J Bone Joint Surg Am (1986) 2.78
Giant cell tumor of bone: treatment and outcome of 214 cases. J Cancer Res Clin Oncol (2008) 2.63
Giant cell tumor of long bone: a Canadian Sarcoma Group study. Clin Orthop Relat Res (2002) 2.60
Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet (2013) 2.53
Does curettage without adjuvant therapy provide low recurrence rates in giant-cell tumors of bone? Clin Orthop Relat Res (2005) 2.51
Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res (2009) 2.51
Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res (2012) 2.46
Local recurrence of giant cell tumor of bone after intralesional treatment with and without adjuvant therapy. J Bone Joint Surg Am (2008) 2.21
Cryosurgery in the treatment of giant cell tumor. A long-term followup study. Clin Orthop Relat Res (1999) 2.12
Giant cell tumor of the extremity: A review of 349 cases from a single institution. Cancer Treat Rev (2009) 1.89
Giant cell tumor of bone: review, mimics, and new developments in treatment. Radiographics (2013) 1.86
Giant cell tumor of bone: risk factors for recurrence. Clin Orthop Relat Res (2010) 1.84
Cement is recommended in intralesional surgery of giant cell tumors: a Scandinavian Sarcoma Group study of 294 patients followed for a median time of 5 years. Acta Orthop (2008) 1.83
Metastases from histologically benign giant-cell tumor of bone. J Bone Joint Surg Am (1984) 1.78
Benign giant-cell tumor of bone with pulmonary metastases: clinical findings and radiologic appearance of metastases in 13 cases. AJR Am J Roentgenol (1992) 1.77
Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: a case-control study. Bone (2007) 1.77
Periprosthetic infection in patients treated for an orthopaedic oncological condition. J Bone Joint Surg Am (2005) 1.77
Giant-cell tumour of bone metastasising to the lungs. A long-term follow-up. J Bone Joint Surg Br (1998) 1.76
Curettage of benign bone tumors without grafts gives sufficient bone strength. Acta Orthop (2009) 1.73
RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone. Am J Clin Pathol (2002) 1.72
Customized treatment algorithm for giant cell tumor of bone: report of a series. Clin Orthop Relat Res (2002) 1.63
Giant cell tumor of the sacrum and spine: series of 23 cases and a review of the literature. Iowa Orthop J (2010) 1.61
Giant cell tumor of bone. Curettage and cement reconstruction. Clin Orthop Relat Res (1995) 1.58
Radiotherapy in the management of giant cell tumor of bone. Int J Radiat Oncol Biol Phys (2003) 1.57
Recurrence of curetted and bone-grafted giant-cell tumours with and without adjuvant phenol therapy. Eur J Surg Oncol (2001) 1.55
Results of giant cell tumor of bone treated with intralesional excision. Clin Orthop Relat Res (2004) 1.50
Pulmonary metastasis of benign giant cell tumor of bone. Six histologically confirmed cases, including one of spontaneous regression. Clin Orthop Relat Res (1994) 1.50
Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 1.44
Total sacrectomy and reconstruction: oncologic and functional outcome. Clin Orthop Relat Res (2000) 1.44
Histologically verified lung metastases in benign giant cell tumours--14 cases from a single institution. Int Orthop (2006) 1.43
Long-term follow-up of patients with giant cell tumor of the sacrum treated with selective arterial embolization. Cancer (2002) 1.39
Long-term follow-up of efficacy and safety of megavoltage radiotherapy in high-risk giant cell tumors of bone. Int J Radiat Oncol Biol Phys (1995) 1.38
Giant-cell tumors of bone: an analysis of 87 cases. Int Orthop (2004) 1.34
Serial arterial embolization for large sacral giant-cell tumors: mid- to long-term results. Spine (Phila Pa 1976) (2007) 1.33
Phenol as an adjuvant for local control in the treatment of giant cell tumour of the bone. Eur J Surg Oncol (1999) 1.31
Giant-cell tumor of the appendicular skeleton. Clin Orthop Relat Res (2002) 1.31
Giant cell tumors of the axial skeleton. Sarcoma (2012) 1.29
Treatment and outcome of giant cell tumors of the pelvis. Acta Orthop (2009) 1.28
Radiation therapy for giant cell tumors of bone. Clin Orthop Relat Res (2003) 1.28
Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB. Am J Pathol (2005) 1.26
Treatment options for recurrent giant cell tumors of bone. J Cancer Res Clin Oncol (2008) 1.24
Curettage of giant cell tumor of bone. Factors influencing local recurrences and metastasis. Chir Organi Mov (1990) 1.22
Recurrent giant cell tumor of long bones: analysis of surgical management. Clin Orthop Relat Res (2010) 1.21
Cryosurgery in aggressive, benign, and low-grade malignant bone tumours. Lancet Oncol (2005) 1.20
High-Speed Burring with and without the Use of Surgical Adjuvants in the Intralesional Management of Giant Cell Tumor of Bone: A Systematic Review and Meta-Analysis. Sarcoma (2010) 1.19
Late complications and survival of endoprosthetic reconstruction after resection of bone tumors. Clin Orthop Relat Res (2010) 1.17
Surgical treatment of primary tumors of the sacrum. Arch Orthop Trauma Surg (2001) 1.15
Megavoltage radiation therapy for axial and inoperable giant-cell tumor of bone. J Bone Joint Surg Am (1999) 1.14
Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone. BMC Cancer (2010) 1.13
The treatment of sacral giant-cell tumours by serial arterial embolisation. J Bone Joint Surg Br (2002) 1.13
Treatment of giant cell tumors with allograft transplants: a 30-year study. Clin Orthop Relat Res (2005) 1.11
Outcome of conservative surgery for giant cell tumor of the sacrum. Spine (Phila Pa 1976) (2009) 1.11
Conservative surgery for giant cell tumors of the sacrum. The role of cryosurgery as a supplement to curettage and partial excision. Cancer (1994) 1.11
Giant cell tumour of the sacrum: a suggested algorithm for treatment. Eur Spine J (2010) 1.10
Recruitment of osteoclast precursors by stromal cell derived factor-1 (SDF-1) in giant cell tumor of bone. J Orthop Res (2005) 1.10
Cathepsin K is the principal protease in giant cell tumor of bone. Am J Pathol (2004) 1.10
Curettage of giant cell tumor of bone. The effect of surgical technique and adjuvants on local recurrence rate. Chir Organi Mov (1990) 1.09
The megavoltage radiation therapy in treatment of patients with advanced or difficult giant cell tumors of bone. Int J Radiat Oncol Biol Phys (2009) 1.09
RANKL, denosumab, and giant cell tumor of bone. Curr Opin Oncol (2012) 1.09
Factors affecting prognosis of patients with giant cell tumors of the mobile spine: retrospective analysis of 102 patients in a single center. Ann Surg Oncol (2012) 1.08
Morphological and immunophenotypic features of primary and metastatic giant cell tumour of bone. Virchows Arch (2009) 1.07
Cryosurgery in the treatment of giant cell tumors of bone: a report of 52 consecutive cases. Clin Orthop Relat Res (1979) 1.05
Does the addition of cement improve the rate of local recurrence after curettage of giant cell tumours in bone? J Bone Joint Surg Br (2011) 1.05
Radiotherapy in the management of giant cell tumor of bone. Am J Clin Oncol (2013) 1.04
Musculoskeletal tumors: does fast dynamic contrast-enhanced subtraction MR imaging contribute to the characterization? Radiology (1998) 1.03
MR findings indicative of hemosiderin in giant-cell tumor of bone: frequency, cause, and diagnostic significance. AJR Am J Roentgenol (1996) 1.03
Complications associated with bone cementing for the treatment of giant cell tumors of bone. J Orthop Sci (2002) 1.03
Radiation therapy in the treatment of giant cell tumor of bone. Int J Radiat Oncol Biol Phys (1999) 1.01
Bone and soft tissue tumors: the role of contrast agents for MR imaging. Eur J Radiol (2000) 0.99
RANKL-independent human osteoclast formation with APRIL, BAFF, NGF, IGF I and IGF II. Bone (2010) 0.99
Giant cell tumor of the hand: superior results with curettage, cryosurgery, and cementation. J Hand Surg Am (2001) 0.98
Efficacy of radiotherapy for giant cell tumor of bone: given either postoperatively or as sole treatment. Int J Radiat Oncol Biol Phys (2001) 0.97
Joint salvage for pathologic fracture of giant cell tumor of the lower extremity. Clin Orthop Relat Res (2007) 0.96
Long bones giant cells tumors: treatment by curretage and cavity filling cementation. Orthop Traumatol Surg Res (2009) 0.95
The efficacy of chemical adjuvants on giant-cell tumour of bone. An in vitro study. J Bone Joint Surg Br (2010) 0.95
Impending fractures in giant cell tumours of the distal femur: incidence and outcome. Int Orthop (2006) 0.94
Telomere reduction in giant cell tumor of bone and with aging. Cancer Genet Cytogenet (1993) 0.94
Radiation therapy in the treatment of difficult giant cell tumors. Int J Radiat Oncol Biol Phys (1989) 0.94
Giant cell tumors of the knee: subchondral bone integrity affects the outcome. Int Orthop (2005) 0.93
Giant cell tumour of bone: a new evaluating system is necessary. Int Orthop (2012) 0.92
Recurrence after and complications associated with adjuvant treatments for sacral giant cell tumor. Clin Orthop Relat Res (2010) 0.92
Radiation therapy for giant cell tumor of bone. Int J Radiat Oncol Biol Phys (1993) 0.92
A short-term in vivo model for giant cell tumor of bone. BMC Cancer (2011) 0.92
Role of adjuvant cryosurgery in intralesional treatment of sacral tumors. Cancer (2003) 0.91
The closed cryosurgical treatment of giant cell tumor. Clin Orthop Relat Res (1985) 0.91
Mid-term outcome after curettage with polymethylmethacrylate for giant cell tumor around the knee: higher risk of radiographic osteoarthritis? J Bone Joint Surg Am (2013) 0.91
Giant cell tumor with pathologic fracture: should we curette or resect? Clin Orthop Relat Res (2013) 0.90
Targeted approaches in the treatment of osteoporosis: differential mechanism of action of denosumab and clinical utility. Ther Clin Risk Manag (2012) 0.90
Dynamic contrast-enhanced MR imaging of musculoskeletal tumors: basic principles and clinical applications. J Magn Reson Imaging (1997) 0.90
CCAAT/enhancer binding protein beta is up-regulated in giant cell tumor of bone and regulates RANKL expression. J Cell Biochem (2010) 0.89
Similar local control between phenol- and ethanol-treated giant cell tumors of bone. Clin Orthop Relat Res (2011) 0.89
Secondary malignant giant-cell tumour of bone: molecular abnormalities of p53 and H-ras gene correlated with malignant transformation. Histopathology (2001) 0.89
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet (2004) 11.37
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet (2012) 8.00
Sarcoma derived from cultured mesenchymal stem cells. Stem Cells (2006) 3.40
The clinical approach towards chondrosarcoma. Oncologist (2008) 3.01
Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst (2007) 2.85
Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med (2012) 2.82
Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nat Genet (2011) 2.74
Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J Clin Oncol (2010) 2.61
Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res (2009) 2.51
Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? Eur J Cancer (2011) 2.23
Frequent truncating mutations of STAG2 in bladder cancer. Nat Genet (2013) 2.20
Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcoma. J Pathol (2010) 2.17
Technical considerations in CT-guided radiofrequency thermal ablation of osteoid osteoma: tricks of the trade. AJR Am J Roentgenol (2002) 2.10
Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. J Clin Oncol (2012) 2.02
Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol (2012) 2.02
Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. Eur J Cancer (2005) 2.01
Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. J Pathol (2009) 1.96
Langerhans-cell histiocytosis 'insight into DC biology'. Trends Immunol (2003) 1.85
Digital fibromyxoma (superficial acral fibromyxoma): a detailed characterization of 124 cases. Am J Surg Pathol (2012) 1.83
DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours. Histopathology (2010) 1.78
Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol (2009) 1.78
Lymphatics and bone. Hum Pathol (2007) 1.76
Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination. J Clin Endocrinol Metab (2010) 1.72
Enchondromatosis: insights on the different subtypes. Int J Clin Exp Pathol (2010) 1.67
Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. J Clin Oncol (2010) 1.65
Cartilage tumours and bone development: molecular pathology and possible therapeutic targets. Nat Rev Cancer (2010) 1.63
Assessment of interobserver variability and histologic parameters to improve reliability in classification and grading of central cartilaginous tumors. Am J Surg Pathol (2009) 1.63
Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. Clin Cancer Res (2008) 1.60
Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol (2009) 1.60
Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin Cancer Res (2010) 1.57
Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev (2009) 1.57
Adherence and patients' experiences with the use of oral anticancer agents. Acta Oncol (2013) 1.56
A nation-wide study comparing sporadic and familial adenomatous polyposis-related desmoid-type fibromatoses. Int J Cancer (2010) 1.56
Incidence, predictive factors, and prognosis of chondrosarcoma in patients with Ollier disease and Maffucci syndrome: an international multicenter study of 161 patients. Oncologist (2011) 1.54
Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents. Clin Cancer Res (2011) 1.53
Outcome of advanced, unresectable conventional central chondrosarcoma. Cancer (2014) 1.51
Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort. Genes Chromosomes Cancer (2010) 1.50
Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer. Int J Cancer (2004) 1.49
Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia. Cancer Res (2005) 1.49
Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol (2010) 1.48
RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline. Eur Radiol (2009) 1.44
Identification of a novel, recurrent HEY1-NCOA2 fusion in mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression data. Genes Chromosomes Cancer (2011) 1.44
The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target. J Pathol (2010) 1.43
Phase II multicenter clinical trial of pulmonary metastasectomy and isolated lung perfusion with melphalan in patients with resectable lung metastases. J Thorac Oncol (2014) 1.42
Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer (2011) 1.41
Translating pharmacogenomics: challenges on the road to the clinic. PLoS Med (2007) 1.39
[Vertebroplasty: a treatment option for osteoporotic compression fractures]. Ned Tijdschr Geneeskd (2010) 1.38
The role of EXT1 in nonhereditary osteochondroma: identification of homozygous deletions. J Natl Cancer Inst (2007) 1.37
Cement leakage in percutaneous vertebroplasty for osteoporotic vertebral compression fractures: identification of risk factors. Spine J (2011) 1.37
Factors affecting cytochrome P-450 3A activity in cancer patients. Clin Cancer Res (2004) 1.36
Proximal humerus reconstruction after tumour resection: biological versus endoprosthetic reconstruction. Int Orthop (2010) 1.34
Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res (2005) 1.33
EWSR1-CREB1 and EWSR1-ATF1 fusion genes in angiomatoid fibrous histiocytoma. Clin Cancer Res (2007) 1.33
Diffusion-weighted MRI in the characterization of soft-tissue tumors. J Magn Reson Imaging (2002) 1.33
Functional characterization of osteosarcoma cell lines provides representative models to study the human disease. Lab Invest (2011) 1.32
Somatic loss of maternal chromosome 11 causes parent-of-origin-dependent inheritance in SDHD-linked paraganglioma and phaeochromocytoma families. Oncogene (2004) 1.32
The NFATc2 gene is involved in a novel cloned translocation in a Ewing sarcoma variant that couples its function in immunology to oncology. Clin Cancer Res (2009) 1.31
Soft-tissue tumors: value of static and dynamic gadopentetate dimeglumine-enhanced MR imaging in prediction of malignancy. Radiology (2004) 1.31
Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment. Lancet Oncol (2005) 1.30
Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours. J Pathol (2010) 1.29
Langerhans cell histiocytosis: fascinating dynamics of the dendritic cell-macrophage lineage. Immunol Rev (2010) 1.28
Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment. Cancer Res (2013) 1.28
Prognostic factors in pulmonary metastasized high-grade osteosarcoma. Pediatr Blood Cancer (2010) 1.27
Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors. J Clin Oncol (2009) 1.26
Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab. Clin Cancer Res (2011) 1.24
Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors. Anticancer Drugs (2014) 1.24
Genome-wide analysis of Ollier disease: Is it all in the genes? Orphanet J Rare Dis (2011) 1.24
Concise review: mesenchymal tumors: when stem cells go mad. Stem Cells (2011) 1.23
NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. Mol Immunol (2008) 1.23
Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. J Clin Oncol (2009) 1.23
Kinome profiling of chondrosarcoma reveals SRC-pathway activity and dasatinib as option for treatment. Cancer Res (2009) 1.22
Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review. Oncologist (2011) 1.22
Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis. J Clin Oncol (2013) 1.21
Local recurrence of myxofibrosarcoma is associated with increase in tumour grade and cytogenetic aberrations, suggesting a multistep tumour progression model. Mod Pathol (2006) 1.21
Identification of markers to characterize and sort human articular chondrocytes with enhanced in vitro chondrogenic capacity. Arthritis Rheum (2007) 1.20
The CpG island methylator phenotype: what's in a name? Cancer Res (2013) 1.20
Diagnosis and prognosis of chondrosarcoma of bone. Expert Rev Mol Diagn (2002) 1.19
Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. Int J Radiat Oncol Biol Phys (2011) 1.18
Estrogen signaling is active in cartilaginous tumors: implications for antiestrogen therapy as treatment option of metastasized or irresectable chondrosarcoma. Clin Cancer Res (2005) 1.18
No genomic aberrations in Langerhans cell histiocytosis as assessed by diverse molecular technologies. Genes Chromosomes Cancer (2009) 1.18